CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
Cetuximabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00499031
NCT00499031Phase 2Completed
CompareCT.gov

A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix

Gynecologic Oncology Group·interventional·Posted Jul 11, 2007·Updated Jan 13, 2015

In Brief

A Phase 2 clinical trial evaluating Cetuximab for Cervical Squamous Cell Carcinoma and Recurrent Cervical Carcinoma. Completed, enrolled 38 participants across 22 sites.

Detailed Summary

This phase II trial is studying cetuximab to see how well it works in treating patients with persistent or recurrent cervical cancer. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 11, 2007
Enrollment StartJun 1, 2007
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 19.0 years ago

Interventions

Cetuximabbiological

Given IV